home

conferences

ascrs

ASCRS

Videos

Tibor Juhasz, CEO of ViaLase, Inc, discusses the company's development of a novel, noninvasive high-resolution OCT image-guided femtosecond laser technology for the treatment of open-angle glaucoma.

ViaLase CEO talks innovations in glaucoma treatment

Articles

CXL is safe, effective to perform on younger population, study results show.

Collagen crosslinking provides corneal stability in young patients

Sheryl brings a wealth of editorial experience to MJH Life Sciences’ Eye Care Network, having engaged with the readers and the greater ophthalmic community of 

for more than 20 years. As Group Editorial Director, Sheryl’s purview extends across the print and digital network of 

Ophthalmology Times, Ophthalmology Times Europe, Modern Retina 

 Prior to ophthalmology, Sheryl previously covered the fields of audiology and confectionery science/technology/manufacturing.

Sheryl is also passionate about the mission, vision and values of Ophthalmic World Leaders (OWL) and recently completed her term on its Board of Directors. She continues to volunteer as Editor-in-Chief of the organization’s 

Magazine. In 2013, she was honored with the group’s inaugural Rising Star Award.

In addition, she has served as a judge for 

 Health Care Heroes Awards program as well as the Jesse H. Neal National Business Journalism Awards.

George O. Waring IV, MD, FACS, discusses the latest results from the GEMINI 1 clinical trial of AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia.

Analyzing GEMINI 1 clinical trial results of presbyopia eye drop

Steven Greenstein, MD, reports on the 10-year postop data from an epi-off corneal collagen cross-linking treatment in keratoconus and ectasia patients.

Examining 10-year postop data on epi-off CXL for keratoconus, ectasia 

COO JD Schaub provides an overview of how RVL Pharmaceuticals has shifted toward becoming an ocular aesthetics company, with the sole purpose to fully focus on UPNEEQ®. 

RVL Pharmaceuticals: Shifting toward ocular aesthetics 

Michael Rivers, MD, discusses the impact of Aetna's new policy requiring prior authorization for cataract surgery on ophthalmologists, their workflow, and patients. 

How new prior authorization policy affects cataract surgery

Michael Rivers, MD, discusses how Modernizing Medicine's latest updates to its electronic health records EMA® system benefits both ophthalmologists and optometrists. 








Modernizing Medicine: New EHR innovations benefits eye care physicians 

Ophthalmologists and industry executives share what lingers on their minds at the end of the day.



What keeps you up at night in ophthalmology: Part VI

Robert Weinstock, MD, discusses the efficacy and safety of intracameral dexamethasone suspension 9% compared to standard of care topical regimen for eyes receiving cataract surgery.

Evaluating efficacy, safety of intracameral dexamethasone 9% vs topical regimen for cataract surgery

Cathleen McCabe, MD, shares an overview of results from a retrospective study highlighting the effectiveness of dexamethasone intraocular suspension 9% following cataract surgery.